Merck to Present New Data from its Broad Oncology Portfolio and Pipeline at the ASCO20 Virtual Scientific Program

Off #MRK, Corporate News, Health, Health Information, Human Health, Latest News, Life Sciences, Medicine, Merck, Merck Pharmaceutical, NYSE:MRK, Oncology, Oncology Newsroom, Pharmaceuticals, Research and Development News, Science and Health, Science and Research

Dateline City:
KENILWORTH, N.J.

ASCO Plenary Session to Feature Phase 3 Data for KEYTRUDA®(pembrolizumab) in MSI-H/dMMR Colorectal Cancer

New and Long-Term Data with KEYTRUDA in More than 15 Tumor Types Including Triple-Negative Breast Cancer, Classical Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma and Melanoma

New Findings for LYNPARZA® (olaparib) and KEYTRUDA plus LENVIMA® (lenvatinib)

First-Time Data with Merck’s Investigational, Oral HIF-2α Inhibitor (MK-6482) in Patients with Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new data from its oncology program will be presented at the 2020 American Society of Clinical Oncology (ASCO20) Virtual Scientific Program from May 29-31.

Language:
English

Contact:

Media Contacts:

Pamela Eisele
(267) 305-3558

Kristen Drake
(908) 740-1679

Investor Contacts:

Peter Dannenbaum
(908) 740-1037

Courtney Ronaldo
(908) 740-6132

Ticker Slug:
Ticker:
MRK

Exchange:
NYSE

@Merck

read more

Read Original Article: Merck to Present New Data from its Broad Oncology Portfolio and Pipeline at the ASCO20 Virtual Scientific Program »

About The Author